首页> 外文期刊>Echocardiography. >The effect of different circadian blood pressure rhythms on left ventricular systolic dyssynchrony in patients with newly diagnosed essential hypertension.
【24h】

The effect of different circadian blood pressure rhythms on left ventricular systolic dyssynchrony in patients with newly diagnosed essential hypertension.

机译:不同昼夜血压节律对新诊断的新诊断性高血压患者左心室收缩性脱蛋白的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this work was to develop new chitosan nanospheres for the delivery of 5-fluorouracil (5-FU). Drug loaded nanospheres were prepared using a technique derived from a combination of coacervation and emulsion droplet coalescence methods. The size and morphology of nanospheres were characterized by laser light scattering and transmission electron microscopy. The 5-FU interaction with chitosan nanospheres was investigated by DSC analysis and FT-IR spectroscopy. The in vitro release was studied by dialysis bag technique. Cytotoxicity of 5-FU loaded chitosan nanospheres was evaluated in vitro on HT29 and PC-3 cell lines. The effects of 5-FU loaded chitosan nanospheres on adhesion of tumor cells to human umbilical vein endothelial cells (HUVEC) were also investigated. 5-FU loaded chitosan nanospheres appeared with a spherical shape, with a mean diameter of about 200 nm and a negative zeta potential of about - 6.0 mV. The successful interaction between drug and chitosan nanosphere matrix was demonstrated by both DSC and FT-IR analyses. The quantitative determination of 5-FU was assayed by UV-Vis analysis. The encapsulation efficiency of 5-FU content was about 70%. A kinetic study of in vitro release demonstrated that the percentages of 5-FU delivered from nanospheres was approx. 10% after 3 hours. The in vitro studies showed that 5-FU loaded nanospheres were effective in reducing tumor cell proliferation in a time- and concentration-dependent manner. 5-FU nanospheres were also able to inhibit both HT29 and PC-3 adhesion to HUVEC after 48 hours of treatment.
机译:这项工作的目的是开发新的壳聚糖纳米球,用于递送5-氟尿嘧啶(5-FU)。使用衍生自共制和乳液液滴结合方法的技术制备药物负载纳米球。通过激光散射和透射电子显微镜表征纳米球的尺寸和形态。通过DSC分析和FT-IR光谱研究了与壳聚糖纳米球的5-FU相互作用。通过透析袋技术研究了体外释放。在HT29和PC-3细胞系上在体外评价5-FU负载壳聚糖纳米球的细胞毒性。还研究了5-FU负载的壳聚糖纳米球对肿瘤细胞对人脐静脉内皮细胞(HUVEC)的粘附作用。 5-FU负载的壳聚糖纳米球出现球形,平均直径约为200nm,负Zeta电位为约-6.0mV。通过DSC和FT-IR分析证明了药物和壳聚糖纳米球基质之间的成功相互作用。通过UV-VIS分析测定5-FU的定量测定。 5-FU含量的封装效率约为70%。体外释放的动力学研究表明,从纳米球中递送的5-FU百分比约为约。 3小时后10%。体外研究表明,5-FU负载的纳米球有效地以时间和浓度依赖性的方式降低肿瘤细胞增殖。在治疗48小时后,5-FU纳米球还能够抑制HT29和PC-3对HUVEC的粘附。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号